業績

呼吸器内科論文一覧

<2016年>

  1. Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, Fukuoka M. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Sci,107(12): 1837-1842, 2016
  1. Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Hozumi H, Tamura T. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Ann Oncol,27(12): 2242-2250, 2016
  1. Horinouchi H. The prospect of patritumab for treating non-small cell lung cancer. Expert Opin Biol Ther,16(12): 1549-1555, 2016
  1. Horinouchi H. Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective. Jpn J Clin Oncol,46(12): 1174-1178, 2016
  1. Kataoka T, Kiyota N, Shimada T, Funakoshi Y, Chayahara N, Toyoda M, Fujiwara Y, Nibu K, Komori T, Sasaki R, Mukohara T, Minami H. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx,43(6): 677-684, 2016
  1. Saruwatari K, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ohe Y, Goto K. Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy. Clin Lung Cancer,17(6): 581-587, 2016
  1. Hida T, Nakagawa K, Seto T, Satouchi M, Nishio M, Hotta K, Takahashi T, Ohe Y, Takeda K, Tatsuno M, Asakawa T, Shimada T, Tanaka T, Tamura T. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ NSCLC with or without prior crizotinib therapy. Cancer Sci,107(11): 1642-1646, 2016
  1. Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, Iwasa S, Ochiai A, Yamamoto N, Fujiwara Y, Tamura K Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer,15: 73, 2016
  1. Tamura Y, Nokihara H, Honda K, Tanabe Y, Asahina H, Yamada Y, Enatsu S, Kurek R, Yamamoto N, Tamura T Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol,78: 995-1002, 2016
  1. Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Amagai M, Yamazaki N. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget,7: 77404-77415, 2016
  1. Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drug,34: 596-603, 2016
  1. Noda S, Kanda S. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. Expert Rev Respir Med,10: 547-556, 2016
  1. Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, Nakano T, Tsuchiya T, Tsubochi H, Komura D, Aburatani H, Dobashi Y, Nakajima J, Endo S, Fukayama M, Sekido Y, Niki T, Murakami Y. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci,107(10): 1527-1538, 2016
  1. Minami H, Ando Y, Ma BB, Hsiang Lee J, Momota H, Fujiwara Y, Li L, Fukino K, Ito K, Tajima T, Mori A, Lin CC. Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. Cancer Sci,107(10): 1477-1483, 2016
  1. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open,29;1(5): e000097, 2016
  1. Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer,99: 186-193, 2016
  1. Katsuya Y, Horinouchi H, Asao T, Kitahara S, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Watanabe S, Tsuta K, Ohe Y. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer,99: 4-10, 2016
  1. Makino Y, Watanabe M, Makihara RA, Nokihara H, Yamamoto N, Ohe Y, Sugiyama E, Sato H, Hayashi Y. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients. Asia Pac J Clin Oncol,12: 259-264, 2016
  1. Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, Matsumoto S, Takano A, Shimizu K, Goto A, Tsuta K, Watanabe S, Ohe Y, Watanabe Y, Goto Y, Nokihara H, Furuta K, Yoshida A, Goto K, Hishida T, Tsuboi M, Tsuchihara K, Miyagi Y, Nakayama H, Yokose T, Tanaka K, Nagashima T, Ohtaki Y, Maeda D, Imai K, Minamiya Y, Sakamoto H, Saito A, Shimada Y, Sunami K, Saito M, Inazawa J, Nakamura Y, Yoshida T, Yokota J, Matsuda F, Matsuo K, Daigo Y, Kubo M, Kohno T. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. Nat Commun,9;7: 12451, 2016
  1. Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T; JCOG0605 investigators. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol,17(8): 1147-1157, 2016
  1. Fujiwara Y, Hamada A, Mizugaki H, Aikawa H, Hata T, Horinouchi H, Kanda S, Goto Y, Itahashi K, Nokihara H, Yamamoto N, Ohe Y. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci,107(8): 1117-1123, 2016
  1. Tagami K, Kashiwase Y, Yokoyama A, Nishimura H, Miyano K, Suzuki M, Shiraishi S, Matoba M, Ohe Y, Uezono Y. The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor. Neuropeptides,58: 93-101, 2016
  1. Shimomura A, Fujiwara Y, Kondo S, Kodaira M, Iwasa S, Kitano S, Tanabe Y, Tamura K, Yamamoto N. Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy,8: 9-15, 2016
  1. Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol,78: 281-288, 2016
  1. Zenda S, Ota Y, Tachibana H, Ogawa H, Ishii S, Hashiguchi C, Akimoto T, Ohe Y, Uchitomi Y. A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. J Radiat Res,57(3): 301-306, 2016
  1. Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, Hashigaki S, Nagasawa T, Umeyama Y, Yoshino T. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci,107: 755-763, 2016
  1. Miura N, Kamita M, Kakuya T, Fujiwara Y, Tsuta K, Shiraishi H, Takeshita F, Ochiya T, Shoji H, Huang W, Ohe Y, Yamada T, Honda K. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget,31;7(22): 33165-7, 2016
  1. Niho S, Nokihara H, Nihei K, Akimoto T, Sumi M, Ito Y, Yoh K, Goto K, Ohmatsu H, Horinouchi H, Yamamoto N, Sekine I, Kubota K, Ohe Y, Tamura T. Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Survival and Recurrent Sites. Am J Clin Oncol,39(2): 132-5, 2016
  1. Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol,77: 767-776, 2016
  1. Asao T, Fujiwara Y, Sunami K, Kitahara S, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Ichikawa H, Kohno T, Tsuta K, Watanabe S, Takahashi K, Ohe Y. Medical treatment involving investigational drugs and genetic profile of thymic carcinoma. Lung Cancer,93: 77-81, 2016
  1. Sunami K, Furuta K, Tsuta K, Sasada S, Izumo T, Nakaoku T, Shimada Y, Saito M, Nokihara H, Watanabe S, Ohe Y, Kohno T. Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues. J Thorac Oncol 11: 203-212, 2016
  1. Nokihara H, Yamamoto N, Ohe Y, Hiraoka M, Tamura T. Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-Small Cell Lung Cancer. Clin Ther,38: 338-347, 2016
  1. Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe SI, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Oncologis,21: 156-164, 2016
  1. Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Int J Clin Oncol,22(1): 70-78, 2016
  1. Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T. Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Int J Clin Oncol,22(1): 79, 2016
  1. Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M. Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. Invest New Drugs,35(1): 37-46, 2016
  1. Nokihara H, Yamada Y, Fujiwara Y, Yamamoto N, Wakui H, Nakamichi S, Kitazono S, Inoue K, Harada A, Taube T, Takeuchi Y, Tamura T. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs,34: 66-74, 2016
  1. Horinouchi H. Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer. Transl Lung Cancer Res,5(1): 78-81, 2016
  2. Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Tamura T, Ohe Y. Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. Int J Radiat Oncol Biol Phys,94: 155-162, 2016
  1. Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol,27: 185-192, 2016
  1. Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, Tamura K, Hamada A. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep,6: 1977, 2016
  1. Horie M, Tamiya H, Goto Y, Suzuki M, Matsuzaki H, Hasegawa WT, Noguchi S, Kawakami M, Matsuta K, Nagase T, Sakamoto Y. Nonspecific elevation of serum Aspergillus galactomannan antigen levels in patients with rheumatoid arthritis. Respir Investig,54(1): 44-49, 2016
  1. Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Tomioka H, Umezu M, Otsuki N, Nibu K, Minami H. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. Cancer Chemother Pharmacol,77(2): 281-288,2016

<2015年>

  1. Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer, 90(3): 477-83, 2015
  1. Matsumura Y, Umemura S, Ishii G, Tsuta K, Matsumoto S, Aokage K, Hishida T, Yoshida J, Ohe Y, Suzuki H, Ochiai A, Goto K, Nagai K, Tsuchihara K. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma. J Cancer Res Clin Oncol, 141:2159-2170, 2015
  1. Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K, Ishii G. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung. J Cancer Res Clin Oncol, 141:2121-2130, 2015
  1. Sekiguchi M, Sekine S, Sakamoto T, Otake Y, Nakajima T, Matsuda T, Taniguchi H, Kushima R, Ohe Y, Saito Y. Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion. J Gastroenterol, 50:1184-1189, 2015
  1. Tamura Y, Fujiwara Y, Yamamoto N, Nokihara H, Horinouchi H, Kanda S, Goto Y, Kubo E, Kitahara S, Tsuruoka K, Tsuta K, Ohe Y. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes, 8:800, 2015
  1. Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 76:1153-1161, 2015
  1. Fujiwara Y, Nokihara H, Yamada Y, Yamamoto N, Sunami K, Utsumi H, Asou H, Takahashi O, Ogasawara K, Gueorguieva I, Tamura T. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 76:1143-1152, 2015
  1. Fujiwara Y, Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda M, Ajiki T, Takashima Y, Yoshimura K, Hamada A, Minami H, and Ioka T. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PLoS One, 10(12):e0143072: 2015
  1. Sugiyama E, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Ohe Y, Goto K. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer, 90: 307-313, 2015
  1. Mizugaki H, Yamamoto N, Nokihara H, Fujiwara Y, Horinouchi H, Kanda S, Kitazono S, Yagishita S, Xiong H, Qian J, Hashiba H, Shepherd SP, Giranda V, Tamura T. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol, 76(5):1063-1072, 2015
  1. Motonaga M, Yamamoto N, Makino Y, Ando-Makihara R, Ohe Y, Takano M, Hayashi Y. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer:evaluation of drug-drug interaction. Cancer Chemother Pharmacol, 76:713-721, 2015
  1. Asao T, Nokihara H, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Yamamoto N, Sekine I, Kunitoh H, Fujiwara Y, Ohe Y. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer. Jpn J Clin Oncol, 45:941-946, 2015
  1. Yagishita S, Horinouchi H, Sunami KS, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T, Ohe Y. Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer. Cancer Sci, 106:1402-1407, 2015
  1. Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer, 89:287-293, 2015
  1. Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe SI, Asamura H, Tamura T, Ohe Y. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer. Clin Lung Cancer, 16:385-390, 2015
  1. Udagawa H, Ishii G, Morise M, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Goto K, Ochiai A, Ohe Y. Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung. J Cancer Res Clin Oncol, 141:1417, 2015
  1. Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs, 33(4):881-889, 2015
  1. Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N. Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Sci Rep, 5:13076, 2015
  1. Katsuya Y, Fujiwara Y, Sunami K, Utsumi H, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Takashima Y, Osawa S, Ohe Y, Tamura T, Hamada A. Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer. Cancer Chemother Pharmacol, 76:125-132, 2015
  1. Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T: Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs, 33:632-640, 2015
  1. Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, Horinouchi H, Nagashima M, Sekiguchi M, Tamura T. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer, 88:275-281, 2015
  1. Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Fujiwara Y, Tamura Y, Wakui H, Honda K, Mizugaki H, Kitazono S, Tanabe Y, Asahina H, Yamazaki N, Suzuki S, Matsuoka M, Ogita Y, Tamura T. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. Invest New Drugs, 33:641-651, 2015
  1. Mizugaki H, Yamamoto N, Fujiwara Y, Nokihara H, Yamada Y, Tamura T. Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization. J Clin Oncol, 33:2051-2061, 2015
  1. Kitazono S, Fujiwara Y, Nakamichi S, Mizugaki H, Nokihara H, Yamamoto N, Yamada Y, Inukai E, Nakamura O, Tamura T. A phase I study of resminostat in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 75:1155-1161, 2015
  1. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med, 37:1689-1699, 2015
  1. Takahashi A, Ishii G, Neri S, Yoshida T, Hashimoto H, Suzuki S, Umemura S, Matsumoto S, Yoh K, Niho S, Goto K, Ohmatsu H, Nagai K, Gemma A, Ohe Y, Ochiai A. Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth. Oncotarget, 6:9531-9541, 2015
  1. Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T, Asamura H, Kawaishi M, Kuwano K, Ochiya T. The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther, 23(4):717-27: 2015
  1. Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, Iwamoto Y, Saka H, Mizusawa J, Shibata T, Nakamura S, Ando M, Yokoyama A, Nakagawa K, Saijo N, Tamura T. Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L. J Clin Oncol, 33:575-581, 2015
  1. Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Niimi A, Nagai K, Ohe Y, Ochiai A. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res, 21:642-654, 2015
  1. Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, Shiomi H, Kubo S, Ikuta S, Yanagimoto H,Terajima H, Ikoma H, Sakai D, Kodama Y, Seo S, Morita S, Ajiki T, Nagano H, Ioka T. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol, 75(2):293-300: 2015
  1. Tsukada H, Yokoyama A, Goto K, Shinkai T, Harada M, Ando M, Shibata T, Ohe Y, Tamura T, Saijo N; for the Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer:Japan Clinical Oncology Group (JCOG) 0207. Jpn J Clin Oncol, 45:88-95, 2015
  1. Eba J, Shimokawa T, Nakamura K, Shibata T, Misumi Y, Okamoto H, Yamamoto N, Ohe Y; on behalf of the Lung Cancer Study Group of the Japan Clinical Oncology Group. A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201). Jpn J Clin Oncol, 45:115-118, 2015
  1. Yagishita S, Horinouchi H, Katsui Taniyama T, Nakamichi S, Kitazono S, Mizugaki H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Sumi M, Shiraishi K, Kohno T, Furuta K, Tsuta K, Tamura T. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 91:140-148, 2015

<2014年>

  1. Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci, 105:1584-1590, 2014
  1. Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, Toyoda M, Kiyota N, Mukohara T, Nishiumi S, Azuma T, Yoshida M, Minami H. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS One, 9:e113259, 2014
  1. Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, Saka H, Okamoto H, Takayama K, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, Yamamoto N, Nukiwa T, Nakanishi Y. Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respir Investig, 52:339-347, 2014
  1. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol, 15:1236-1244, 2014
  1. Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, Takemura S, Kubo S, Yanagimoto H, Toyokawa H, Tsuji A, Terajima H, Morita S, Ioka T. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol, 74:699-709, 2014
  1. Mizugaki H, Fujiwara Y, Yamamoto N, Yagishita S, Kitazono S, Tanaka A, Horinouchi H, Kanda S, Nokihara H,Tsuta K, Asamura H, Tamura T. Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases. Jpn J Clin Oncol, 44:835-840, 2014
  1. Morise M, Niho S, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y. Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer. Jpn J Clin Oncol, 44:846-851, 2014
  1. Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, Niho S, Yoh K, Matsumoto S, Takahashi A, Morise M, Nakamura Y, Ochiai A, Nagai K, Iwakawa R, Kohno T, Yokota J, Ohe Y, Esumi H, Tsuchihara K, Goto K. Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. J Thorac Oncol, 9:1324-3131, 2014
  1. Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H, Watanabe S, Tsuta K, Kumamoto K, Takenoshita S, Yokota J, Harris CC, Kohno T. A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Clin Cancer Res, 20:4784-4793, 2014
  1. Blackhall F, Kim DW, Besse B, Nokihara H, Han JY, Wilner KD, Reisman A, Iyer S, Hirsh V, Shaw AT. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol, 9:1625-1633, 2014
  1. Fujiwara Y, Toyoda M, Chayahara N, Kiyota N, Shimada T, Imamura Y, Mukohara T, Minami H.Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. PLoS One, 9(8):e104215, 2014
  1. Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer, 14: 530-537, 2014
  1. Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, Horiike A, Nakagawa K, Terashima M, Okabe T, Kaneda H, McKee MD, Carlson DM, Xiong H, Tamura T.A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol, 74(1):37-43, 2014
  1. Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K, Takahashi K. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS One, 9:e102436, 2014
  1. Sai K, Kurose K, Koizumi T, Katori N, Sawada J, Matsumura Y, Saijo N, Yamamoto N, Tamura T, Okuda H, Saito Y. Distal promoter regions are responsible for differential regulation of human orosomucoid-1 and -2 gene expression and acute phase responses. Biol Pharm Bull, 37:164-168, 2014
  1. Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A, Tsuji A, Kaihara S, Ikoma H, Takemura S, Toyokawa H, Terajima H, Morita S, Ioka T.Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer Chemother Pharmacol, 73:1295-301, 2014
  1. Wakui H, Yamamoto N, Kitazono S, Mizugaki H, Nakamichi S, Fujiwara Y, Nokihara H, Yamada Y, Suzuki K, Kanda H, Akinaga S, Tamura T. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 74:15-23, 2014
  1. Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res, 20:3087-3093, 2014
  1. Taniyama TK, Nokihara H, Tsuta K, Horinouchi H, Kanda S, Fujiwara Y, Yamamoto N, Koizumi F, Yunokawa M, Tamura T. Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analyses. Clin Lung Cancer, 15:244-7, 2014
  1. Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, Satouchi M, Kiura K, Nogami N, Endo M, Watanabe H, Tamura T. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer, 84:67-72, 2014
  1. Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509. J Clin Oncol, 33:1262-1268, 2014
  1. Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, Watanabe S, Yamamoto N, Tamura T, Asamura H. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Jpn J Clin Oncol, 44:379-382, 2014
  1. Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y. Protective Effect of Magnesium Preloading on Cisplatin-Induced Nephrotoxicity: A Retrospective Study. Jpn J Clin Oncol, 44:346-354, 2014
  1. Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y, Tamura T. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol, 73:511-516, 2014
  1. Yagishita S, Horinouchi H, Yorozu T, Kitazono S, Mizugaki H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Mori T, Tsuta K, Sumi M, Tamura T. Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer. Jpn J Clin Oncol, 44:191-194, 2014
  1. Hishida T, Yoshida J, Ohe Y, Aokage K, Ishii G, Nagai K. Surgical Outcomes after Initial Surgery for Clinical Single-station N2 Non-small-cell Lung Cancer. Jpn J Clin Oncol , 44:85-92, 2014

<2013年>

  1. Asahina H, Nokihara H, Yamamoto N, Yamada Y, Tamura Y, Honda K, Seki Y, Tanabe Y, Shimada H, Shi X, Tamura T. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Invest New Drugs 31(3): 677-84, 2013
  1. Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Umezu M, Otsuki N, Nibu K, Minami H. Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Japanese Journal of Clinical Oncology. 43(3): 271-7, 2013
  1. Ekyalongo RC, Mukohara T, Kataoka Y, Funakoshi Y, Tomioka H, Kiyota N, Fujiwara Y, Minami H. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. Investigational New Drugs. 31(2): 293-303, 2013
  2. Fujiwara Y, Ando Y, Mukohara T, Kiyota N, Chayahara N, Mitsuma A, Inada-Inoue M, Sawaki M, Ilaria R Jr, Kellie Turner P, Funai J, Maeda K, Minami H. A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors.. Cancer Chemother Pharmacol 71(4): 991-8, 2013
  1. Nakamichi S, Kubota K, Horinouchi H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T. Successful EGFR-TKI Rechallenge of Leptomeningeal Carcinomatosis after Gefitinib-induced Interstitial Lung Disease. Japanese Journal of Clinical Oncology 43(4): 422-5, 2013
  1. Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, Hayashi N, Kawano S, Fujiwara Y, Minami H, Takenawa T, Azuma T, Yoshida M. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.. Cancer Epidemiology, Biomarkers & Prevention. 22(4): 571-9, 2013
  1. Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Investigational New Drugs 31(5): 1158-68, 2013
  1. Fujiwara Y, Chayahara N, Mukohara T, Kiyota N, Tomioka H, Funakoshi Y, Minami H. Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. Oncology Report 30(4): 1802-6, 2013
  1. Yamamoto, H. Nokihara, Y. Yamada, K. Uenaka, R. Sekiguchi, T. Makiuchi, C.A. Slapak, K.A. Benhadji, T. Tamura, Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 71;1645-1655:2013
  1. Nishio, T. Horai, A. Horiike, H. Nokihara, N. Yamamoto, T. Takahashi, H. Murakami, F. Koizumi, K. Nishio, W. Yusa, N. Koyama, T. Tamura, Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer 109;538-544: 2013
  1. Kuroda, I. Sekine, M. Sumi, S. Sekii, K. Takahashi, K. Inaba, H. Horinouchi, H. Nokihara, N. Yamamoto, K. Kubota, N. Murakami, M. Morota, H. Mayahara, Y. Ito, T. Tamura, K. Nemoto, J. Itami, Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer. Technol Cancer Res Treat 12;333-339. 2013
  1. Honda, N. Yamamoto, H. Nokihara, Y. Tamura, H. Asahina, Y. Yamada, S. Suzuki, N. Yamazaki, Y. Ogita, T. Tamura,  Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. . Cancer Chemother Pharmacol 72; 577-584: 2013
  1. Goto, M. Nishio, N. Yamamoto, K. Chikamori, T. Hida, M. Maemondo, N. Katakami, T. Kozuki, H. Yoshioka, T. Seto, T. Fukuyama, T. Tamura,  A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 82;109-114. 2013
  1. Horinouchi H, Sekine I, Sumi M, Noda K, Goto K, Mori K, Tamura T. Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.. Cancer Sci. 104(1);:93-7: 2013
  1. Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43(11);1105-9: 2013

<2012年>

  1. Yamamoto, H. Nokihara, Y. Yamada, Y. Goto, M. Tanioka, T. Shibata, K. Yamada, H. Asahina, T. Kawata, X. Shi, T. Tamura. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci .103: 504-509, 2012
  1. Sekine, M. Sumi, Y. Ito, H. Horinouchi, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, K. Kubota, T. Tamura. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 82: 953-959, 2012
  1. Seki, N. Yamamoto, Y. Tamura, Y. Goto, T. Shibata, M. Tanioka, H. Asahina, H. Nokihara, Y. Yamada, T. Shimamoto, K. Noguchi, T. Tamura. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol .69:1099-1105, 2012
  1. Minami-Shimmyo, Y. Ohe, S. Yamamoto, M. Sumi, H. Nokihara, H. Horinouchi, N. Yamamoto, I. Sekine, K. Kubota, T. Tamura. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J Thorac Oncol. 7: 177-182, 2012
  1. Makino, N. Yamamoto, H. Sato, R. Ando, Y. Goto, C. Tanai, H. Asahina, H. Nokihara, I. Sekine, H. Kunitoh, Y. Ohe, E. Sugiyama, N. Yokote, T. Tamura, H. Yamamoto. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer. Cancer Chemother Pharmacol. 69: 861-869, 2012
  1. A. Makihara, Y. Makino, N. Yamamoto, N. Yokote, H. Nokihara, I. Sekine, Y. Ohe, T. Tamura, H. Yamamoto. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy. Jpn J Clin Oncol. 42: 187-1191, 2012
  1. Goto, I. Sekine, M. Tanioka, T. Shibata, C. Tanai, H. Asahina, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, H. Kikkawa, E. Ohki, T. Tamura. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer.. Invest New Drugs .30: 1548-1556, 2012
  1. Asahina, Y. Tamura, H. Nokihara, N. Yamamoto, Y. Seki, T. Shibata, Y. Goto, M. Tanioka, Y. Yamada, A. Coates, Y.L. Chiu, X. Li, R. Pradhan, P.J. Ansell, E.M. McKeegan, M.D. McKee, D.M. Carlson, T. Tamura. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol .69: 1477-1486, 2012
  1. Asahina, I. Sekine, H. Horinouchi, H. Nokihara, N. Yamamoto, K. Kubota, T. Tamura. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 13: 39-43, 201.
  1. Horinouchi H, Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Ohe Y, Tamura T. Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. Cancer Sci. 103(4): 756-9, 2012
  1. Nokihara H, Yamamoto N, Yamada Y, Yamada K, Hirata T, Goto Y, Tanioka M Ikeda Y, Tamura T. A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol.70(4): 559-65, 2012
  1. Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Sakai D, Kodama Y, Ajiki T, Nagano H, Ioka T. Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). Cancer Chemotherapy and Pharmacology. 69(5): 1181-8, 2012
  1. Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investigational New Drugs.30(3): 1055-64, 2012
    ,
  2. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H.Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Investigational New Drugs.30(4);1352-60, 2012
    ,
  3. Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y, Minami H.Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. International Journal of Oncology.41(2);551-8:2012
  4. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Investigational New Drugs.30(5);1950-7:2012

<2011年>

  1. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F:Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor Breast Cancer Res. 13:R66:2011
  1. Taguchi F, Kodera Y, Katanasaka Y, Yanagihara K, Tamura T, Koizumi F:Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal Invest New Drugs. 29:1198-1205:2011
  1. Takahashi T, Yamamoto N, Tamura T, Kunitoh H, Nishiwaki Y, Negoro S:Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by ONCOLOGY LETTERS. 2:1033-1040:2011
  1. Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, Yokota J, Suzuki K, Asamura H, Furuta K, Tsuda H:The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung Lung Cancer. 73:45-50:2011
  1. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T:Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid Cancer Chemother Pharmacol. 68:505-511:2011
  1. Katori N, Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Yomota C, Kawanishi T, Nishimaki- Mogami T, Naito M, Sawada JI, Kunitoh H, Nokihara H, Sekine I, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Yamamoto N, Okuda H, Tamura T:Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer J Pharm Sci.  100:4546-4559:2011
  1. Ohyanagi F, Horai T, Sekine I, Yamamoto N, Nakagawa K, Nishio M, Senger S, Morsli N, Tamura  T:Safety  of  BLP25  Liposome Vaccine (L-BLP25) in Japanese Patients with Unresectable Stage III NSCLC after Primary Chemoradiotherapy: Preliminary Results from a Phase I/II Jpn J Clin Oncol. 41:718-722:2011
  1. Ueda Y, Shimoyama T, Murakami H, Yamamoto N, Yamada Y, Arioka H, Tamura T:Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol. 67:1101-1109:2011
  1. Murakami H, Ueda Y, Shimoyama T, Yamamoto N, Yamada Y, Arioka H, Tamura  T:Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid Cancer Chemother Pharmacol. 67:1119-1128:2011
  1. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T:Phase I Dose Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Clin Cancer Res. 17:2528-2537:2011
  1. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada JI, Saijo N, Yoshida T, Tamura T: Genome・ Wide Association Study on Overall Survival of Advanced Non・small Cell Lung Cancer Patients Treated with Carboplatin and J Thorac Oncol. 6:132-138:2011
  1. Sekine I, Kubota K, Tamura Y, Asahina H, Yamada K, Horinouchi H, Nokihara H, Yamamoto N, Tamura T: Innovator and generic cisplatin formulations: comparison of renal Cancer Sci. 102:162-165:2011
  1. Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima・Uesaka H, Sugimoto D, Kurose K, Sai K, Kaniwa N, Sawada JI, Kunitoh H, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Okuda H, Tamura  T:Genetic  polymorphisms  and haplotypes of POR encoding cytochrome P450 oxidoreductase in a Japanese Drug Metab Pharmacokinet. 26:107-116:2011
  1. Doi T, Tahara M, Yoshino T, Yamazaki K, Tamura T, Yamada Y, Yang BB, Oliner KS, Otani S, Asahi D: Tumor KRAS Status Predicts Responsiveness to Panitumumab in Japanese Patients with Metastatic Colorectal Cancer. Jpn J Clin Oncol. 41:210-216:2011
  1. Furugen M, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T:Combination chemotherapy with carboplatin and paclitaxel for advanced thymic Jpn J Clin Oncol. 41:1013-1016:2011
  1. Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T: Amrubicin monotherapy for patients with previously treated advanced large・cell neuroendocrine carcinoma of the Jpn J Clin Oncol. 41:897-901:2011
  1. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M:Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese J Thorac Oncol. 6:2011-2017:2011
このページは役に立ちましたか?

役に立った 役に立たなかった

6人中6人がこのページは役に立ったと言っています。